Background: Epidemiologic studies have suggested different prevalence of neuromyelitis optica (NMO) in different ethnic groups. However, data on the incidence and prevalence of NMO in Caucasians are scarce.
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease (IDD) of the CNS and probably the most common IDD apart from multiple sclerosis (MS). [1] [2] [3] NMO is considered to be a rare disorder in Caucasians, but this view is based on few studies with small patient populations from tertiary hospitals. [4] [5] [6] [7] No population-based studies have been carried out so far in Caucasians.
The main clinical features of NMO consist of optic neuritis (ON) and acute transverse myelitis (TM). Longitudinally extensive TM (LETM) or more limited TM from the cervical spine reaching into the brainstem is regarded as typical for NMO. 2, [8] [9] [10] [11] NMO follows a relapsing course in 80%-90% of cases, is more common in females, and is associated with older age. Serum immunoglobulin G (IgG) aquaporin 4 (AQP4) antibodies have been shown to be a highly specific (85-99%) but less sensitive (58 -76%) serum biomarker for NMO. [12] [13] [14] Based on AQP4 antibody determinations, NMO has recently been recognized to have a more heterogeneous clinical presentation, including clinical signs or lesions in the CNS outside of the optic nerve and spinal cord. 11, 15, 16 NMO has a poor prognosis so early diagnosis based on robust criteria is critical. Several diagnostic criteria have been suggested, notably the Wingerchuk criteria, 5, 11 and the US National Multiple Sclerosis Society (NMSS) criteria. 17 The aim of the present study was to estimate the incidence and prevalence of NMO in the Region of Southern Denmark based on the Wingerchuk 2006 criteria. 11 METHODS Setting. The Region of Southern Denmark is one of 5 administrative units in Denmark established January 1, 2007, with a 12,191 km 2 area and a geographically well-defined population. The adult population (Ն15 years of age) of the Region in 2006 -2008 was 952,000. Of the total population, 94.1% were ethnic Danes and 5.9% were immigrants.
The Region has 4 hospital units with neurology departments including MS clinics to which all patients with demyelinating disorders of the CNS are referred from private practice (neurologists and general practitioners). Treatment is free of charge for the patient. The Region had 4 ophthalmology departments at the time, but information could only be obtained from 3 as one department closed and their patients were referred to the other departments in the Region.
Data sources.
As the primary data source the neurology and ophthalmology departments of the Region were asked to report patients who obtained a diagnosis of MS, NMO, TM, or ON during the time period January 1, 1998 -December 31, 2008. A separate registration for patients with MS treated with biological therapy (natalizumab) was available from the neurologic departments because this treatment is centralized to university hospitals. These data were used as a supplementary source of information.
All Danish citizens are identified by a unique personal identification number facilitating a cross-check of data with information from The Danish National Patient Registry (DNPR) where all hospital visits including outpatient contacts are registered. Residents in the Region of Southern Denmark who during the time period 1998 -2008 appeared in DNPR with a diagnosis of MS, ON, TM, or NMO (WHO ICD-10 codes: G 37.3, G35, G360, H46.9) were identified.
Study population. The study population was established based on the following inclusion criteria: 1) episodes of ON or TM and 2) an initial brain MRI (obtained within the first year of the onset of symptoms) that did not meet diagnostic criteria for MS at disease onset (McDonald dissemination in space criteria). 18, 19 A total of 99.2% of the patient population were Caucasian.
Study design.
The study was a population-based retrospective consecutive case series with longitudinal follow-up. Information was provided from a questionnaire, a clinical examination, reevaluation of all MRIs, supplementary MRIs, visual evoked potentials (VEP), and serum AQP4 antibody determination.
Diagnosis. The diagnosis of NMO was based on the criteria of
Wingerchuk et al. 11 For comparison, the diagnostic criteria for NMO from the NMSS 17 were used (table 1). The diagnostic process was performed in 3 independent parts. 19 Spinal cord MRI were reported as normal, as LETM (cord lesion extending 3 or more vertebral segments) on T2weighted MRI and hypointensities on T1-weighted images when obtained during acute episodes of myelitis, or abnormal with a smaller lesion not suggestive of NMO. 11, 20 The neuroradiologist had no prior knowledge of clinical history or re- sults of other investigations. MRI data were reported in a written form by the neuroradiologist. Integration of clinical data and imaging was made by the neurologist and established the clinical NMO diagnosis. 3. Anti-AQP4 antibodies were determined. The laboratory staff was blinded to the clinical status of patients when performing the assay.
The final diagnosis of NMO was based on the clinical data and anti-AQP-4 antibody positivity.
Laboratory methods. IgG AQP4 antibodies were measured with a recombinant immunofluorescence assay using HEK293 cells transfected with recombinant human full-length AQP4 gene (Euroimmun, Lubeck, Germany). Patient sera were screened at a 1:10 dilution. Analyses were done in an accredited laboratory at the Department of Clinical Immunology, Odense University Hospital.
Statistical methods. Incidence rates were calculated as the number of patients with NMO during the follow-up period divided by the total numbers of person-years at risk and reported per 10 5 person-years. Prevalence was estimated as a percentage in the IDD groups and as number of cases per 10 5 persons in the total population. Means, medians, and ranges were calculated and 95% confidence intervals (CI) were estimated. All data analyses were performed in STATA version 11. MS. Of the 86 patients from the at-risk MS group, 28 (33%) were classified as NMO, 19 on purely clinical grounds based on the association of ON, LETM, and absence of brain changes suggestive of MS, 5 and 9 additionally with positive anti-AQP4 antibodies. A total of 54% of patients with NMO from the MS group were positive for serum anti-AQP4 antibodies.
Standard protocol approvals, registrations, and patient
Previously diagnosed NMO. The 5 patients with NMO diagnosed during 1998 -2008 all had definite NMO. Three were positive for anti-AQP4 antibodies. Two patients were previously found positive for anti-AQP4 antibodies as measured by another assay (Seelig Labs, Karlsruhe, Germany). One died before blood sampling and one, who received azathioprine therapy, was negative for anti-AQP4 antibodies when analyzed in the present study.
TM. The TM group consisted of 28 patients. Of those, 13 had single TM, 7 had LETM, and 9 had relapsing TM. Four were classified as having NMO based on positive anti-AQP4 antibodies, 3 LETM, and one recurrent TM. Two of the patients with LETM developed ON later during the study period and were reclassified as definite NMO. The patient with recurrent TM developed bilateral ON and later a cervical LETM, which led to respiratory failure and death. 15 were applied, 28 of the patients also fulfilled these criteria. The 14 patients who did not fulfill the NMSS criteria were all AQP4 antibody-positive including 8 patients from the MS group who did not have LETM and 6 from the limited NMO group.
Incidence and prevalence. The prevalence of NMO in the at-risk MS group was 33%. In the total MS group (including patients with MS who did not fulfill the inclusion criteria), the prevalence was 17%. In the total number of patients with MS, TM, and ON, the prevalence was 26%. The yearly incidence rate of NMO in the population was estimated at 0.4 per 10 5 person-years (95% CI 0.30 -0.54) and the prevalence was 4.4 per 10 5 (95% CI 3.1-5.7). depicted in table 3 . At disease onset, 24 of the 36 patients with definite NMO had TM, 15 of whom had evaluable MRI at spinal cord; 6 (40%) of these had LETM. At follow-up, 28 of the 36 (78%) had had events of LETM. Five patients had cervical TM that led to respiratory failure and intractable hiccups and nausea; 3 died during the study period. Brainstem symptoms occurred in 2 at disease onset, increasing to 26 (72%) at follow-up.
Clinical manifestations. Clinical characteristics are
All patients with definite NMO followed a relapsing course. A total of 34 (81%) patients were in remission at the time of investigation. Patients with NMO were assigned Expanded Disability Status Scale (EDSS) score (table 3) . Three patients died, at 63, 56, and 47 years of age, during the study period.
CSF. Complete CSF analysis was available at disease onset for 32 of the 42 patients. CSF abnormalities were detected in 27 (table 3) .
MRI-CNS. The Regional Health Service was not obligated by law to keep radiologic investigations for more than 5 years and reports of radiologic examinations for more than 10 years, so a significant proportion of MRIs at disease onset were unavailable. Supplementary MRI of brain was performed in 58 and supplementary MRI of spinal cord in 108 patients. All patients who were diagnosed with definite or limited NMO in the study had evaluable MRI of brain at disease onset. Character- Anti-AQP4 antibodies. Anti-AQP4 antibodies were positive in 26/42 (62%) patients. Antibody positivity was necessary to confirm the diagnosis in 15 cases (36%), whereas 27 (64%) were diagnosed solely on clinical criteria. Fifty patients with MS were examined clinically and radiologically verifying the MS diagnosis and were used as disease controls together with 50 healthy controls. None were positive for anti-AQP4 antibodies.
DISCUSSION In this study including longitudinal follow-up for a decade we found a yearly incidence rate of NMO in the Region of Southern Denmark of 0.4 per 10 5 person-years (95% CI 0.30 -0.54) and a prevalence of 4.4 per 10 5 (95% CI 3.1-5.7). The study estimated the incidence and prevalence of NMO in a Caucasian population. Among the patients with the most common IDD, the prevalence of NMO was 26% (95% CI 19%-32%). In the total MS group, the prevalence was 17%, and in the at-risk MS group 33%. These data are at variance with a multicenter study from Italy 21 of NMO in patients with IDD, reporting a low prevalence of NMO of 1.5% (95% CI 0.7-2.4) with an MS: NMO ratio of 42.7. The study was not population-based and it is not clear to what extent NMO antibodies (NMO-IgG) was used in the initial diagnosis.
In our study, the diagnosis of NMO by the Wingerchuk 2006 criteria 11 could be made purely on clinical grounds in a high proportion of cases. Similarly, a study from France 22 using the same criteria found that clinical and MRI-based diagnosis of definite NMO was sufficient in 90% of 125 patients with NMO. Furthermore, the clinical phenotype in our study was similar to the results from these 2 studies 21, 22 including the high female:male ratio and the clinical heterogeneity of NMO with TM, LETM, ON, and brainstem syndromes. Danish NMO cases are thus comparable to other Caucasian patients with NMO with regard to the gender distribution and clinical manifestations.
Low sensitivity of AQP4 antibody determination has been observed previously. 12, 14, 21, 22 Antibody titers are probably influenced both by the clinical status and immunosuppressive treatment, and most of the patients in the present study were in remission or on immunomodulatory or immunosuppressive treatment. All 8 patients who had a clinical relapse during the study period were seropositive for anti-AQP4 antibodies. The MS controls and the healthy controls were uniformly negative for AQP4 antibodies. Thus, the present study confirms a high diagnostic specificity and moderate to low sensitivity of anti-AQP4 antibody determination.
A possible limitation of this study was the fact that a lower than expected number of MS cases were reported from the clinical departments. The low number could be due to misclassification of MS as a clinically isolated syndrome, as inflammatory demyelinating disease, or as other disorders. Secondly, identification of newly diagnosed patients in the study period presented difficulties both for the clinical departments and the DNPR, possibly leading to unequal sampling. It has previously been described for rheumatologic diseases that up to 22% of the diagnoses were not correct in the DNPR. 23 Finally, susceptible patients with ON may be seen by ophthalmologists in private practice and with regard to TM by rheumatology departments in the Region.
Another possible limitation of the study was the selection of an at-risk MS group who fulfilled the inclusion criteria. Of those who fulfilled the inclusion criteria, 35 were on natalizumab treatment, which according to general treatment guidelines in the region was given to patients with high disease activity. This strategy may hinder the diagnosis of NMO, but evidently increases the prevalence of NMO in the MS group. Furthermore, it was not possible to retrieve the initial MRI for evaluation in a number of patients. A LETM may appear in multiple shorter plaques (Յ3 vertebral segments) during remission or following treatment with high-dose steroids, and normal appearance or shorter lesions can be found early during relapse or in the residual atrophic stage. 11, 24, 25 This natural development of the disease may limit the number of patients with NMO in the study, as 34 of the total group of patients with NMO were in remission at the time of investigation. Furthermore, the majority of patients received immunosuppressive or immunomodulatory treatment, which further lowered the probability of diagnosing NMO. It may be concluded that the number of patients with NMO found in the study provides a conservative estimate of the incidence and prevalence.
A primary strength of this study was the design of the diagnostic algorithm for NMO, as the clinical diagnosis was established without knowledge of AQP4 antibody results and vice versa, diminishing the risk of bias. All MRIs were reevaluated and supplementary MRI was taken if missing or if a relapse was suspected since the last MRI, giving a high degree of diagnostic completeness. VEP was used as an objective indication of visual pathophysiology in the diagnosis of patients with NMO in the study. VEP abnormalities were observed in 86% of the patients with NMO, suggesting that VEP analysis may support the diagnosis of NMO. 6 We discovered a number of patients with NMO in a predominantly Caucasian population. A consequence of this finding is that NMO may be considered a more obvious differential diagnosis than previously thought in diagnostic algorithms for MS as well as for ON and TM. We observed heterogeneity of clinical disease manifestations similar to the findings of previous studies. 21, 22 Future studies may relate the diverse clinical findings in NMO to the immunogenetic background, e.g., the human leukocyte antigen distribution. Furthermore, other forms of autoimmunity seem to be prevalent in patients with NMO and could be more closely delineated.
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